Accelerator Based Neutron Beams for Neutron Capture Therapy
The DOE-funded accelerator BNCT program at the Massachusetts Institute of Technology has resulted in the only operating accelerator-based epithermal neutron beam facility capable of generating significant dose rates in the world. With five separate beamlines and two different epithermal neutron beam assemblies installed, we are currently capable of treating patients with rheumatoid arthritis in less than 15 minutes (knee joints) or 4 minutes (finger joints) or irradiating patients with shallow brain tumors to a healthy tissue dose of 12.6 Gy in 3.6 hours. The accelerator, designed by Newton scientific Incorporated, is located in dedicated laboratory space that MIT renovated specifically for this project. The Laboratory for Accelerator Beam Applications consists of an accelerator room, a control room, a shielded radiation vault, and additional laboratory space nearby. In addition to the design, construction and characterization of the tandem electrostatic accelerator, this program also resulted in other significant accomplishments. Assemblies for generating epithermal neutron beams were designed, constructed and experimentally evaluated using mixed-field dosimetry techniques. Strategies for target construction and target cooling were implemented and tested. We demonstrated that the method of submerged jet impingement using water as the coolant is capable of handling power densities of up to 6 x 10(sup 7) W/m(sup 2) with heat transfer coefficients of 10(sup 6)W/m(sup 2)-K. Experiments with the liquid metal gallium demonstrated its superiority compared with water with little effect on the neutronic properties of the epithermal beam. Monoenergetic proton beams generated using the accelerator were used to evaluate proton RBE as a function of LET and demonstrated a maximum RBE at approximately 30-40 keV/um, a finding consistent with results published by other researchers. We also developed an experimental approach to biological intercomparison of epithermal beams and compared the RBE characteristics of the MIT Reactor M67 clinical beam, The Brookhaven Medical Research Reactor clinical beam (both of which were used in Phase I/II clinical trials of BNCT) and the MIT LABA BNCS beam. Additional research initiated under this program involved an investigation of the potential of BNCT for the prevention of restenosis and the development of accelerator-based fast neutron brachytherapy. A total of 10 student research theses (2 Undergraduate, 4 Masters, and 4 Doctoral) were completed as part of this research program.
- Research Organization:
- Massachusetts Institute of Technology, Cambridge, MA
- Sponsoring Organization:
- USDOE - Office of Energy Research (ER)
- DOE Contract Number:
- FG02-89ER60874
- OSTI ID:
- 900616
- Country of Publication:
- United States
- Language:
- English
Similar Records
An epithermal neutron beam from the MURR and from an accelerator source compared to the beam at the BMRR
An epithermal neutron beam from the MURR and from an accelerator source compared to the beam at the BMRR